Edition:
United Kingdom

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

26.62USD
15 Dec 2017
Change (% chg)

$0.36 (+1.37%)
Prev Close
$26.26
Open
$26.58
Day's High
$27.35
Day's Low
$26.58
Volume
652,915
Avg. Vol
75,403
52-wk High
$27.35
52-wk Low
$7.81

Latest Key Developments (Source: Significant Developments)

Concert Pharmaceuticals reports Q3 earnings per share $5.61
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update.Q3 earnings per share $5.61.Q3 revenue $143.8 million.Q3 revenue view $11,700 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Concert Pharmaceuticals Inc - ‍Expects cash, cash equivalents and investments as of September 30, 2017 to be sufficient to fund company into 2021​.  Full Article

Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial.Concert Pharmaceuticals Inc - ‍phase 2a trial on track to complete in second half of 2018​.  Full Article

Concert Pharma Says PTAB denies Incyte petition challenging CTP-543 patent
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharma says patent trials and appeal board of u.s. patent and trademark office has denied Incyte's petition to institute IPR​.  Full Article

Concert Pharmaceuticals Q2 loss per share $0.60
Tuesday, 9 Aug 2016 

Concert Pharmaceuticals Inc : Concert Pharmaceuticals reports second quarter 2016 financial results and provides company update . Q2 loss per share $0.60 .Q2 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.  Full Article

Concert Pharma initiates phase 1 trial of CTP-543
Thursday, 19 May 2016 

Concert Pharmaceuticals : Expects to report top-line data upon completion of multiple-dose phase 1 program in q4 of 2016 . Expects to initiate a phase 2 efficacy study in early 2017 .Initiates Phase 1 Trial Of Ctp-543 as a new treatment for alopecia areata.  Full Article

Concert Pharmaceuticals, Inc announces positive data from multiple dose phase 1 Clinical Trial of CTP-656
Thursday, 28 Apr 2016 

Concert Pharmaceuticals, Inc:Positive topline data from a Phase 1 multiple ascending dose clinical trial of CTP-656.CTP-656 is a novel deuterium-modified version of ivacaftor. Ivacaftor is commercially available under the name Kalydeco(reg).Results of the Phase 1 trial also showed that CTP-656 was well-tolerated and its safety profile was comparable to that of Kalydeco.Company expects to present the Phase 1 multiple ascending dose results at the 39(th)European Cystic Fibrosis Conference being held June 8-11, 2016 in Basel, Switzerland.  Full Article

BRIEF-Concert Pharmaceuticals reports Q3 earnings per share $5.61

* Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update